Literature DB >> 3560383

Chlamydia trachomatis infections in the United States. What are they costing us?

A E Washington, R E Johnson, L L Sanders.   

Abstract

Chlamydia trachomatis has emerged as the most common sexually transmitted bacterial pathogen in the United States and is now recognized to cause substantial morbidity. To determine the economic consequences of chlamydial infections in the United States, we analyzed data from local, state, and national sources. We estimate that C trachomatis infections cost Americans over $1.4 billion per year in direct and indirect costs. Chlamydial infections in women account for 79% of this cost, although men and infants are also affected. Three fourths of the total cost is due to sequelae of untreated, uncomplicated infections. If the current rate of chlamydial infection persists, the projected annual costs will exceed $2.18 billion by 1990. Reducing the incidence of personal suffering and heavy economic burden imposed by C trachomatis infections requires establishment and maintenance of effective prevention/control programs.

Entities:  

Mesh:

Year:  1987        PMID: 3560383

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  59 in total

1.  Evaluation of the NucliSens Basic Kit for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in genital tract specimens using nucleic acid sequence-based amplification of 16S rRNA.

Authors:  J B Mahony; X Song; S Chong; M Faught; T Salonga; J Kapala
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

2.  Lower Genital Tract Infections and HIV in Women.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-12       Impact factor: 3.725

3.  Prevalence of sexually transmitted diseases in juvenile prostitutes and street youth.

Authors:  A C Rouget; J K Mah; R A Lang; M R Joffres
Journal:  Can J Infect Dis       Date:  1994-01

4.  Indirect costs in economic studies: confronting the confusion.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

5.  Rapid, on-site diagnosis of chlamydial urethritis in men by detection of antigens in urethral swabs and urine.

Authors:  J Sellors; J Mahony; D Jang; L Pickard; S Castriciano; S Landis; I Stewart; W Seidelman; I Cunningham; M Chernesky
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

6.  Screening for Chlamydia trachomatis in adolescent males: a cost-based decision analysis.

Authors:  A G Randolph; A E Washington
Journal:  Am J Public Health       Date:  1990-05       Impact factor: 9.308

Review 7.  Role of heparan sulfate in sexually transmitted infections.

Authors:  Vaibhav Tiwari; Erika Maus; Ira M Sigar; Kyle H Ramsey; Deepak Shukla
Journal:  Glycobiology       Date:  2012-07-06       Impact factor: 4.313

8.  Chlamydial cervicitis and urethritis: single dose treatment compared with doxycycline for seven days in community based practises.

Authors:  E M Thorpe; W E Stamm; E W Hook; S A Gall; R B Jones; K Henry; G Whitworth; R B Johnson
Journal:  Genitourin Med       Date:  1996-04

9.  Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections.

Authors:  W R Bowie; V Willetts; D W Megran
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

10.  Periodic health examination, 1996 update: 2. Screening for chlamydial infections. Canadian Task Force on the Periodic Health Examination.

Authors:  H D Davies; E E Wang
Journal:  CMAJ       Date:  1996-06-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.